ReviewInflammation and regeneration2016
Complement-targeted therapy: development of C5- and C5a-targeted inhibition.
Review in Inflammation and regeneration, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.
- Use of novel antithrombotic agents for COVID-19: Systematic summary of ongoing randomized controlled trials.Journal of thrombosis and haemostasis : JTH · 2021Pooled it
- Complement C3 overexpression activates JAK2/STAT3 pathway and correlates with gastric cancer progression.Journal of experimental & clinical cancer research : CR · 2020Trial
- The evolving field of nephrology: what comes next? A report from the European Renal Association Scientific Advisory Board.Clinical kidney journal · 2026Review
- Population PK-PD Modeling of Danicopan Add-On Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria Treated With Ravulizumab or Eculizumab.CPT: pharmacometrics & systems pharmacology · 2026Article
- Characterization of gastric ulcer influenced by hot-humid environment and high-sugar and high-fat diet provides a further insight into its underlying mechanism.Scientific reports · 2025Article
- Pioneer: a synthetic human antibody phage display library for rapid therapeutic lead generation.mAbs · 2025Article
- ACSL4 Drives C5a/C5aR1-Calcium-Induced Fibroblast-to-Myofibroblast Transition in a Bleomycin-Induced Mouse Model of Pulmonary Fibrosis.Biomolecules · 2025Article
- Real-World Evidence of the Disease Burden and Economic Impact of Paroxysmal Nocturnal Hemoglobinuria in Italy.Journal of clinical medicine · 2025Article
- Distinct protein patterns related to postnatal development in small for gestational age preterm infants.Pediatric research · 2025Article
- Article
- Epigenetic landscape revealsFrontiers in nutrition · 2025Article
- Identification of a genetic region linked to tolerance to MRSA infection using Collaborative Cross mice.PLoS genetics · 2024Article
- Current Prognostic Biomarkers for Abdominal Aortic Aneurysm: A Comprehensive Scoping Review of the Literature.Biomolecules · 2024Article
- Enhancing prognostic prediction of invasive candidiasis among cancer patients with a serum C5a-based scoring model.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Uncovering mechanisms underlying complement-mediated cancer immune evasion.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- Genetic insight into putative causes of xanthelasma palpebrarum: a Mendelian randomization study.Frontiers in immunology · 2024Article
- Potential Targets and Signaling Mechanisms of Cinnamaldehyde Enhancing Intestinal Function and Nutritional Regulation in Fat Greenling (Aquaculture nutrition · 2024Article
- Review
- Descriptive, real-world treatment patterns, resource use, and total cost of care among eculizumab- and ravulizumab-treated members with paroxysmal nocturnal hemoglobinuria.Journal of managed care & specialty pharmacy · 2023Article
- Properdin inhibition ameliorates hepatic ischemia/reperfusion injury without interfering with liver regeneration in mice.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The complement system is a major effector of humoral immunity and natural immunity. The complement system has three independent pathways of complement activation: a classical pathway, an alternative pathway, and a lectin pathway. These pathways converge to a common pathway that activates C3. This pathway also leads to the formation of various bioactive molecules such as C5a and the formation of membrane attack complex on the surface of target cells. In the past, the only preparations with anti-complementary action were C1 inhibitors (C1-INH), but an anti-C5 monoclonal antibody (eculizumab) appeared a few years ago, and this antibody has yielded encouraging results. In addition, a C5a receptor (C5aR) antagonist is in the clinical trial phase, and this antagonist should also prove efficacious. Anti-complement agents have garnered attention as a new treatment strategy for refractory inflammatory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.